The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy—an open-label, prospective, randomised controlled multicenter study

Felix Rosenow,Jörg Berrouschot,Joachim Springub,G Winkler ,Ilonka Eisensehr,Nicole Burchardi,Sebastian Bauer,Mathias Niedhammer,Philipp S Reif ,Erhard Roth,Stefan Evers,Holger Lerche,Anja Haag,Yvonne G Weber ,Stjepana Kovač ,Wolfgang H Oertel ,Karl Martin Klein,Stephan Arnold,Carmen Schade‐Brittinger ,Adam Strzelczyk,M Schröder ,Susanne Hallmeyer-Elgner,Anja Beige,Hajo M Hamer

doi:10.1136/jnnp-2011-301999

The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy—an open-label, prospective, randomised controlled multicenter study

Felix Rosenow, Jörg Berrouschot + Show 22 more

Open Access

https://doi.org/10.1136/jnnp-2011-301999

Copy DOI

Journal: Journal of Neurology, Neurosurgery & Psychiatry	Publication Date: May 17, 2012
Citations: 53

Affiliation: Universitätsklinikum Gießen und Marburg, Klinikum Altenburger Land, Leopoldina Krankenhaus Schweinfurt, Philipps University of Marburg, Klinikum Oldenburg, University of Münster, University of Ulm, University of Regensburg, TU Dresden

#Lamotrigine #Levetiracetam + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundOf the newer antiepileptic drugs, lamotrigine (LTG) and levetiracetam (LEV) are popular first choice drugs for epilepsy. The authors compared these drugs with regard to their efficacy and tolerability in...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Neurology, Neurosurgery & Psychiatry

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.